Dianthus Therapeutics (DNTH) Registration Filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on developing next-generation therapies for severe autoimmune diseases.

• Lead product candidate, claseprubart, is a novel monoclonal antibody targeting the active form of C1s complement protein, aiming for improved efficacy, safety, and dosing convenience.

• Claseprubart is engineered for potency, extended half-life, and subcutaneous self-administration via pre-filled pen.

Risk factors and disclosures

• Investment involves a high degree of risk, including clinical, regulatory, operational, and market uncertainties.

• Risks include ability to manage expenses, obtain and protect IP, advance clinical programs, secure regulatory approvals, and respond to macroeconomic and geopolitical events.

• Additional risks relate to manufacturing, commercialization, competition, and ability to raise capital.

Use of proceeds and capital allocation

• Net proceeds will support preclinical and clinical development, working capital, and general corporate purposes.

• Proceeds may also be used for licensing, acquiring, or investing in new product candidates, though no current commitments exist.

• Pending use, proceeds may be invested in capital preservation instruments.